Literature DB >> 25675651

Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).

Isis Polianna Silva Ferreira, Samira Buhrer-Sékula, Maria Regina Fernandes De Oliveira, Heitor de Sá Gonçalves, Maria Araci de Andrade Pontes, Maria Lúcia Fernandes Penna, Rossilene Cruz, Gerson Oliveira Penna.   

Abstract

OBJECTIVE: To describe the profile of patients who participated in the Randomised Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR) and determine the level of satisfaction with a uniform therapy regimen, especially among paucibacillary patients.
DESIGN: This is a descriptive cross-sectional epidemiologic study nested in the wider U-MDT/CT-BR. The study was conducted using a convenience sample composed of patients from the Dona Libânia Dermatology Centre in Fortaleza, Ceará and from the Alfredo da Matta Foundation in Manaus, Amazonas in Brazil. The absolute and relative frequencies of categorical variables and the median age were calculated. Hypothesis testing was done using the Chi-squared and Mann-Whitney tests with a 0.05 level of significance.
RESULTS: Of the 859 patients included in the clinical trial, 342 were interviewed. The majority of patients were male (58.2%) and multibacillary (78.3%) with a median age of 42 (7-65) years. Most of the interviewees had not completed primary education (48.0%), earned an income below three times the minimum wage (53.8%), were non-smokers (85.1%), did not regularly consume alcohol (88.3%), had not experienced any leprosy-related discrimination (69.2%) and showed a basic knowledge of the disease. With regards to paucibacillary patients, 87.8% and 90.9% of the PB U-MDT and PB R-MDT groups, respectively, indicated that they had not thought of defaulting treatment at any time. On a satisfaction scale of 1-5 (with five as the highest score), 92.7% of PB U-MDT and 100.0% of PB R-MDT patients gave a mark between three and five.
CONCLUSIONS: The data suggest that the introduction of clofazimine into the therapeutic regimen did not diminish the level of treatment satisfaction among PB patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25675651

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

Review 1.  Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

2.  Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Authors:  Gerson Oliveira Penna; Samira Bührer-Sékula; Lígia Regina Sansigolo Kerr; Mariane Martins de Araújo Stefani; Laura Cunha Rodrigues; Marcelo Grossi de Araújo; Andrea Machado Coelho Ramos; Ana Regina Coelho de Andrade; Maurício Barcelos Costa; Patricia Sammarco Rosa; Heitor de Sá Gonçalves; Rossilene Cruz; Maurício Lima Barreto; Maria Araci de Andrade Pontes; Maria Lúcia Fernandes Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

3.  Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).

Authors:  Emerith Mayra Hungria; Samira Bührer-Sékula; Regiane Morillas de Oliveira; Lúcio Cartaxo Aderaldo; Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Gerson Oliveira Penna; Mariane Martins de Araújo Stefani
Journal:  PLoS Negl Trop Dis       Date:  2017-02-21

4.  Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche.

Authors:  Rossilente Conceiçao Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson de Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

5.  Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Gerson Oliveira Penna; Maria Elisabete Amaral de Moraes; Heitor de Sá Gonçalves; Mariane Martins de Araújo Stefani; Maria Lúcia Fernandes Penna; Maria Araci de Andrade Pontes; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

6.  Unanswered questions on the safety of MDT-U - Reply.

Authors:  Gerson Oliveira Penna; Heitor de Sá Gonçalves; Maria Araci de Andrade Pontes
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

7.  Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.

Authors:  Emerith M Hungria; Samira Bührer-Sékula; Regiane M Oliveira; Lúcio C Aderaldo; Maria Araci A Pontes; Rossilene Cruz; Heitor S de Gonçalves; Maria L F Penna; Gerson O Penna; Mariane M A Stefani
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.